BACKGROUND AND PURPOSE: Matrix metalloproteinases (MMP) may play a role in blood-brain barrier (BBB) disruption after ischemic stroke. We hypothesized that plasma concentrations of MMP-9 are associated with a marker of BBB disruption in patients evaluated for acute stroke. METHODS: Patients underwent MRI on presentation and approximately 24 hours later. The MRI marker, termed hyperintense acute reperfusion injury marker (HARM), is gadolinium enhancement of cerebrospinal fluid on fluid-attenuated inversion recovery MRI. Plasma MMP-9 and tissue inhibitor of matrix metalloproteinase-1 were measured by enzyme-linked immunosorbent assay. Logistic regression models tested for predictors of HARM on 24-hour follow-up scans separately for MMP-9 and the ratio of MMP-9 to TIMP-1. RESULTS: For the 41 patients enrolled, diagnoses were: acute ischemic cerebrovascular syndrome, 33 (80.6%); intracerebral hemorrhage, 6 (14.6%); stroke mimic, 1 (2.4%); and no stroke, 1 (2.4%). HARM was present in 17 (41.5%) patients. In model 1, HARM was associated with baseline plasma MMP-9 concentration (odds ratio [OR], 1.01; 95% confidence interval [CI], 1.001-1.019; P=0.033). In model 2, HARM was associated with the ratio of MMP-9 to tissue inhibitor of matrix metalloproteinase-1 (OR, 4.94; 95% CI, 1.27-19.14; P=0.021). CONCLUSIONS: Baseline MMP-9 was a significant predictor of HARM at 24-hour follow-up, supporting the hypothesis that MMP-9 is associated with BBB disruption. If the association between MMP-9 and BBB disruption is confirmed in future studies, HARM may be a useful imaging marker to evaluate MMP-9 inhibition in ischemic stroke and other populations with BBB disruption.
BACKGROUND AND PURPOSE: Matrix metalloproteinases (MMP) may play a role in blood-brain barrier (BBB) disruption after ischemic stroke. We hypothesized that plasma concentrations of MMP-9 are associated with a marker of BBB disruption in patients evaluated for acute stroke. METHODS:Patients underwent MRI on presentation and approximately 24 hours later. The MRI marker, termed hyperintense acute reperfusion injury marker (HARM), is gadolinium enhancement of cerebrospinal fluid on fluid-attenuated inversion recovery MRI. Plasma MMP-9 and tissue inhibitor of matrix metalloproteinase-1 were measured by enzyme-linked immunosorbent assay. Logistic regression models tested for predictors of HARM on 24-hour follow-up scans separately for MMP-9 and the ratio of MMP-9 to TIMP-1. RESULTS: For the 41 patients enrolled, diagnoses were: acute ischemic cerebrovascular syndrome, 33 (80.6%); intracerebral hemorrhage, 6 (14.6%); stroke mimic, 1 (2.4%); and no stroke, 1 (2.4%). HARM was present in 17 (41.5%) patients. In model 1, HARM was associated with baseline plasma MMP-9 concentration (odds ratio [OR], 1.01; 95% confidence interval [CI], 1.001-1.019; P=0.033). In model 2, HARM was associated with the ratio of MMP-9 to tissue inhibitor of matrix metalloproteinase-1 (OR, 4.94; 95% CI, 1.27-19.14; P=0.021). CONCLUSIONS: Baseline MMP-9 was a significant predictor of HARM at 24-hour follow-up, supporting the hypothesis that MMP-9 is associated with BBB disruption. If the association between MMP-9 and BBB disruption is confirmed in future studies, HARM may be a useful imaging marker to evaluate MMP-9 inhibition in ischemic stroke and other populations with BBB disruption.
Authors: Mar Castellanos; Rogelio Leira; Joaquín Serena; José M Pumar; Ignacio Lizasoain; José Castillo; Antoni Dávalos Journal: Stroke Date: 2003-01 Impact factor: 7.914
Authors: Joan Montaner; Carlos A Molina; Jasone Monasterio; Sonia Abilleira; Juan F Arenillas; Marc Ribó; Manolo Quintana; José Alvarez-Sabín Journal: Circulation Date: 2003-02-04 Impact factor: 29.690
Authors: Mingming Ning; David A Sarracino; Ferdinando S Buonanno; Bryan Krastins; Sherry Chou; David McMullin; Xiaoying Wang; Mary Lopez; Eng H Lo Journal: Transl Stroke Res Date: 2010-12-01 Impact factor: 6.829
Authors: Zurab Nadareishvili; Marie Luby; Richard Leigh; Jignesh Shah; John K Lynch; Amie W Hsia; Richard T Benson; Lawrence L Latour Journal: J Neuroimaging Date: 2017-07-19 Impact factor: 2.486
Authors: Reyna L VanGilder; Danielle M Davidov; Kyle R Stinehart; Jason D Huber; Ryan C Turner; Karen S Wilson; Eric Haney; Stephen M Davis; Paul D Chantler; Laurie Theeke; Charles L Rosen; Todd J Crocco; Laurie Gutmann; Taura L Barr Journal: J Clin Neurosci Date: 2013-08-23 Impact factor: 1.961
Authors: Christopher A Palmiotti; Shikha Prasad; Pooja Naik; Kaisar M D Abul; Ravi K Sajja; Anilkumar H Achyuta; Luca Cucullo Journal: Pharm Res Date: 2014-08-07 Impact factor: 4.200